

Supplemental Online Content

Li Y, Yip M, Ning Y, et al. Topical Atropine for Childhood Myopia Control: The Atropine Treatment Long-Term Assessment Study. *JAMA Ophthalmol*. Published online November 30, 2023.
doi:10.1001/jamaophthalmol.2023.5467

eTable 1. Follow-up Rates of the ATOM Studies

eTable 2. Comparison between the Study Participants and the Residual Participants

eTable 3. Demographics and Characteristics of ATOM2 Study Participants Classified by Myopia Progression from the Final Trial Visit to the Current Study Visit

eFigure 1. Box plots showing the change of mean spherical equivalent (SE) and axial length (AL) from baseline of ATOM1 study participants

eFigure 2. Box plots showing the change of mean spherical equivalent (SE) and axial length (AL) from baseline of ATOM2 study participants

eFigure 3. Line chart showing the change of mean spherical equivalent (SE) and axial length (AL) of ATOM2 study participants over time. Error bars show the standard errors of the means

This supplemental material has been provided by the authors to give readers additional information about their work.

eResults.

The authors have provided these eResults to provide readers additional information about the work.

eTable 1. Follow-up Rates of the ATOM Studies

	ATOM1	ATOM2
Baseline	n = 400	n = 400
2 year	n = 348 (87.0%)	n = 355 (88.8%)
3 year	n = 333 (83.3%)	n = 345 (86.3%)
5 year	NA	n = 328 (82.0%)
Current	<ul style="list-style-type: none">• Contactable (n = 159, 39.8%)<ul style="list-style-type: none">○ Rejected (n = 88, 22.0%)○ Participated (n = 71, 17.8%)	<ul style="list-style-type: none">• Contactable (n = 255, 63.8%)<ul style="list-style-type: none">○ Rejected (n = 97, 24.3%)○ Participated (n = 158, 39.5%)

ATOM = atropine for the treatment of myopia.

eTable 2. Comparison between the Study Participants and the Residual Participants

	ATOM1			ATOM2		
	Study Subject (n = 71)	Residual (n = 329)	P Value	Study Subject (n = 158)	Residual (n = 242)	P Value
Baseline age, mean (SD), years	8.9 (1.4)	9.3 (1.6)	.07	9.5 (1.5)	9.9 (1.6)	.01
Gender, n (% of female)	33 (46.5)	148 (45.0)	.92	76 (48.1)	113 (46.7)	.70
Race, n (% of Chinese)	71 (100.0)	305 (92.7)	.14	144 (91.1)	220 (90.9)	.91
Atropine groups, n (%)	1%: 39 (54.9) Placebo: 32 (45.1)	1%: 161 (48.9) Placebo: 168 (51.1)	.43	0.01%: 31 (19.6) 0.1%: 62 (39.2) 0.5%: 65 (41.1)	0.01%: 53 (21.9) 0.1%: 93 (38.4) 0.5%: 96 (39.7)	.44
SE, mean (SD), D						
Baseline	-3.14 (1.24)	-3.31 (1.34)	.33	-4.70 (1.65)	-4.63 (1.56)	.52
Change of SE*	1.62 (0.94)	1.43 (0.82)	.10	1.79 (1.15)	1.82 (1.11)	.81
AL, mean (SD), mm						
Baseline	24.78 (0.80)	24.91 (0.85)	.23	25.08 (0.89)	25.22 (0.90)	.03
Change of AL*	0.50 (0.49)	0.47 (0.45)	.51	0.83 (0.51)	0.84 (0.50)	.71

ATOM = atropine for the treatment of myopia; SD = standard deviation; SE = spherical equivalent; D = diopters; AL = axial length



*Change of SE/AL: change from baseline visit to final trial visit.

eTable 3. Demographics and Characteristics of ATOM2 Study Participants Classified by Myopia Progression from the Final Trial Visit to the Current Study Visit



	Eyes progressed < 1.0 D (n = 202)	Eyes progressed ≥ 1.0 D (n = 94)	Mean Difference (95% Confidence Interval)	P Value
Baseline age, mean (SD), years	9.7 (1.4)	9.3 (1.5)	0.5 (0.1 to 0.8)	.01
Study age, mean (SD), years	24.5 (1.4)	23.9 (1.5)	0.6 (0.2 to 0.9)	.002
Gender, n (% of female)	97 (48.0)	57 (60.6)	NA	.06
Race, n (% of Chinese)	181 (89.6)	87 (92.6)	NA	.46
Atropine treatment, n (%)				
0.01%	45 (22.3)	11 (11.7)	NA	.03
0.1%	79 (39.1)	43 (45.7)		
0.5%	78 (38.6)	40 (42.6)		
Re-treatment, n (%)	110 (54.5)	64 (68.1)	NA	.03
SE, mean (SD), D				
Baseline	-4.52 (1.52)	-4.60 (1.89)	0.08 (-0.36 to 0.52)	.72
2 year	-4.80 (1.45)	-5.05 (1.83)	0.24 (-0.18 to 0.67)	.26
5 year	-6.14 (1.81)	-6.81 (2.35)	0.68 (0.13 to 1.22)	.01
Current	-6.20 (1.92)	-8.36 (2.66)	2.16 (1.56 to 2.77)	<.001
Change of SE, mean (SD), D				
Baseline to 2 year	-0.29 (0.55)	-0.45 (0.66)	0.16 (-0.00 to 0.33)	.05
Baseline to 5 year	-1.62 (1.02)	-2.21 (1.33)	0.59 (0.29 to 0.90)	<.001
5 year to current	-0.06 (0.54)	-1.55 (0.64)	1.49 (1.34 to 1.64)	<.001
Baseline to current	-1.68 (1.22)	-3.76 (1.63)	2.08 (1.71 to 2.45)	<.001
AL, mean (SD), mm				
Baseline	25.03 (0.89)	25.17 (0.88)	-0.14 (-0.36 to 0.08)	.20
2 year	25.28 (0.92)	25.53 (0.89)	-0.25 (-0.47 to -0.03)	.03
5 year	25.79 (0.99)	26.21 (0.98)	-0.42 (-0.66 to -0.18)	.001
Current	25.99 (1.07)	26.91 (1.20)	-0.92 (-1.20 to -0.63)	<.001
Change of AL, mean (SD), mm				
Baseline to 2 year	0.25 (0.25)	0.36 (0.31)	-0.11 (-0.19 to -0.03)	.02
Baseline to 5 year	0.76 (0.46)	1.04 (0.58)	-0.28 (-0.41 to -0.14)	<.001
5 year to current	0.20 (0.29)	0.70 (0.44)	-0.50 (-0.60 to -0.40)	<.001
Baseline to current	0.96 (0.59)	1.74 (0.84)	-0.78 (-0.97 to -0.59)	<.001

SD = standard deviation; SE = spherical equivalent; D = diopters; AL = axial length.

eFigure 1. Box plots showing the change of mean spherical equivalent (SE) and axial length (AL) from baseline of ATOM1 study participants



eFigure 2. Box plots showing the change of mean spherical equivalent (SE) and axial length (AL) from Baseline of ATOM2 study participants



eFigure 3. Line chart showing the change of mean spherical equivalent (SE) and axial length (AL) of ATOM2 study participants over time. Error bars show the standard errors of the means

